aTyr Pharma aligns with FDA on Phase 3 efzofitimod trial in pulmonary sarcoidosis
ATYR•aTyr Pharma aligned with the FDA on a Phase 3 trial of efzofitimod for chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study activities are expected to start in Q4 2026, and future development is expected to require additional funding.
1. Trial plans
The global, randomized, double-blind trial will test whether efzofitimod improves lung function and patient-reported symptoms versus placebo. aTyr said it is preparing U.S. and European regulatory submissions, with study-related activities expected to start in Q4 2026.
2. Funding needs
The company said future development is expected to require additional funding, potentially through equity or debt financing or partnering. The trial is supported by a previously presented subgroup analysis showing clinically meaningful benefit in the targeted restrictive-lung subgroup.
